Epclusa is the first FDA-approved pangenotypic regimen for the treatment of chronic hepatitis C virus infection. The fixed-dose combination pill contains sofosbuvir 400 mg and velpatasvir 100 mg. Sofosbuvir is sold separately under the brand name Sovaldi. Velpatasvir is a new HCV NS5A inhibitor that is active across all 6 HCV genotypes; it is not sold separately.

If you have a Hayes login, click here to view the full report on the Knowledge Center.